IGF-1 DES
IGF-1 Des(1-3) • Des(1-3)IGF-1
Quick Answer
IGF-1 DES attracts technical queries around half-life, dosing charts, and what differentiates it from related growth-signaling compounds.
Mechanism
Des(1-3) variant of IGF-1 with enhanced potency. Lacks the first 3 amino acids, reducing binding to IGF binding proteins and increasing bioavailability.
Half-Life
20-30 minutes
Administration
Technical Protocol
IGF-1 DES: Comprehensive Research Guide
Overview
IGF-1 DES (Des(1-3)IGF-1) is a truncated form of insulin-like growth factor-1 that lacks the first three amino acids (Glu-Pro-Glu). This modification reduces binding to IGF binding proteins (IGFBPs), resulting in increased bioavailability and enhanced potency compared to standard IGF-1.
Mechanism of Action
Enhanced Bioavailability
- Reduced Binding: Less binding to IGF binding proteins
- Increased Free IGF-1: Higher levels of free, active IGF-1
- Potency: 10-100x more potent than standard IGF-1
- Receptor Binding: Direct binding to IGF-1 receptors
Anabolic Effects
- Muscle Growth: Promotes muscle protein synthesis
- Cell Proliferation: Stimulates cell growth and division
- Recovery: Enhances recovery and repair
- Glucose Uptake: Improves glucose uptake into cells
Research Applications
Muscle Growth Research
- Hypertrophy: Research into muscle growth
- Recovery: Enhanced recovery from exercise
- Performance: Research into athletic performance
- Aging: Research into age-related muscle loss
Metabolic Research
- Glucose Metabolism: Research into glucose control
- Insulin Sensitivity: Improves insulin sensitivity
- Fat Metabolism: May affect fat metabolism
Dosage
- Research: 10-50 mcg daily
- Typical: 20-30 mcg
- Administration: Subcutaneous or intramuscular
- Timing: Post-workout or before bed
Side Effects
- Hypoglycemia: Low blood sugar risk
- Injection Site: Reactions at injection site
- Headache: Possible headaches
- Organ Growth: Theoretical risk of organ enlargement
Storage
- Temperature: -20°C (frozen)
- Light: Protect from light
- Stability: Requires careful storage
This information is for research and educational purposes only.
Answer-First Research Snapshot
Evidence
The page has impressions but weak CTR, making it a strong candidate for title, FAQ, and answer-first improvements.
Dosage Context
Users want dose-chart style clarity, but that guidance should always be paired with route, exposure duration, and evidence quality context.
Status
Keep the framing research-specific and avoid treating growth-signaling interest as proof of general effectiveness.
Surface half-life early.
Answer dose-chart queries explicitly.
Connect to half-life and GH-axis educational content.
Peer-Reviewed Citations
Des(1-3)IGF-1: a more potent form of IGF-1
Ballard FJ, et al. • Endocrinology (1991)
Access ResearchFrequently Asked Questions
Why should IGF-1 DES content mention half-life prominently?
Because half-life is part of how users interpret dose charts, exposure windows, and protocol frequency claims.
How should IGF-1 DES be stored?
Store at -20°C, protect from light
Continue the Research Path
IGF-1 DES: Half-Life, Dose Charts, and Research Interpretation
IGF-1 DES explainer focused on half-life, dose charts, and evidence-aware interpretation.
Peptide Half-Life Explained: Why Timing Changes Everything
Practical guide to peptide half-life, pharmacokinetic assumptions, and why timing claims differ across protocols.
Growth Hormone Releasing Peptides: Mechanisms & Research
Comprehensive analysis of GHRPs and GHRHs, including mechanism-level differences and evidence gaps.
Related Hormonal Peptides
Ipamorelin
A potent and selective growth hormone secretagogue that stimulates growth hormone release.
hormonalCJC-1295 (No DAC)
A modified version of GHRH 1-29, designed to stimulate growth hormone release.
hormonalTesamorelin
The most potent GHRH analog for visceral fat reduction.
hormonalKisspeptin-10
A key regulator of the reproductive axis.